This trial is to see if a medication is safe and effective for people with a disease that causes weakness and numbness.
1 Primary · 19 Secondary · Reporting Duration: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study
Experimental Treatment
360 Total Participants · 1 Treatment Group
Primary Treatment: Efgartigimod PH20 SC · No Placebo Group · Phase 2
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:18 - 65 | 100.0% |
Met criteria | 100.0% |